Your essential biotech, medtech, and pharma recap — no noise, just what matters.

⚡ Executive Takeaway

The Merck KGaA/Bio-Techne deal is a different kind of life sciences M&A. This is not a drug pipeline acquisition. Bio-Techne makes the tools that drug discovery depends on: the recombinant proteins that populate assay panels, the antibodies that validate targets, the reagents that power diagnostic platforms, and the instruments that generate the data. If you work in a pharma or biotech lab, you have used Bio-Techne products. Merck KGaA (which operates as EMD Serono in the U.S. for its healthcare business and MilliporeSigma for its life sciences business) is buying the company to deepen its position as an essential supplier to the industry. The deal gives Merck KGaA a stronger tools portfolio at a time when demand for high quality research reagents is growing with the ADC wave, molecular glue development, and AI driven target discovery programs. Meanwhile, Revolution Medicines showed that its pipeline extends beyond daraxonrasib. The RM-055 combination data, doubling chemo response rates in pancreatic cancer, position a second drug for potential registrational development in the same indication. Two drugs for the same cancer, with different mechanisms, from the same company. That is a franchise, not a one product story. 👉 Read Full Analysis

🔬 Life Sciences Tools

Merck KGaA Acquires Bio-Techne for $11.3B

Merck KGaA agreed to acquire Bio-Techne Corp for $11.3B, expanding its life sciences tools and research reagent portfolio, according to The Pharma Letter. This is Merck KGaA's largest acquisition in more than a decade. Bio-Techne provides recombinant proteins, monoclonal and polyclonal antibodies, immunoassay kits, molecular biology tools, and advanced diagnostic instruments to researchers in pharma, biotech, and academia. The deal strengthens Merck KGaA's MilliporeSigma (U.S. brand) business alongside competitors like Danaher, Thermo Fisher Scientific, and Agilent Technologies in the $80B+ global life sciences tools market. For drug developers: this deal means one of your key reagent suppliers now sits inside a major pharma tools conglomerate.

🔬 Clinical

Revolution's Second RAS Drug Doubles Chemo Response in Pancreatic Cancer RVMD

BioSpace reported on June 25 that Revolution Medicines' RM-055, a catalytic RAS(ON) inhibitor with a different mechanism than daraxonrasib, doubled the chemotherapy response rate in pancreatic cancer in early combination data. This positions Revolution as a two drug pancreatic cancer franchise. Daraxonrasib (RASolute 302, OS HR 0.40, CNPV filing imminent) targets RAS in its active state. RM-055 targets the catalytic function of RAS. If both drugs reach the market, Revolution could offer sequential or combination treatment options that no other oncology company can match in this disease.

Ionis Tryngolza Approved for Severe Hypertriglyceridemia IONS

The FDA approved Ionis Pharmaceuticals' Tryngolza (olezarsen) as the first treatment to reduce the risk of acute pancreatitis in patients with severe hypertriglyceridemia (triglycerides at or above 500 mg/dL), according to Fierce Pharma. This is a meaningful cardiovascular/metabolic approval addressing a condition with significant morbidity and no prior approved risk reduction therapy.

🏢 Corporate

Takeda Formally Appoints Julie Kim as CEO TAK

Takeda formally appointed Julie Kim as president and CEO on June 25, completing an 18 month leadership transition at Japan's largest pharmaceutical company, according to The Pharma Letter. Kim takes the helm as Takeda executes a "transformation program" that includes 4,500 global job cuts (announced May), portfolio simplification, and a strategic pivot toward GI, neuroscience, and rare disease. She is the first woman to lead Takeda and one of the few female CEOs of a top 20 global pharma company.

🌍 Regulatory

FDA Hiring 2,200 to Rebuild After DOGE Cuts

The FDA is hiring approximately 2,200 people to staff up after last year's DOGE related workforce reductions, according to BioSpace reporting from BIO International. The agency is still operating without a permanent commissioner, CDER director, or CBER director, but the hiring initiative signals an effort to restore operational capacity. BioSpace also reported from BIO that the FDA's IND initiative "is a step toward normalization after slipshod year."

📋 The Week in Review

📅 Catalyst Calendar

👉 Read Full Analysis

The Merck KGaA/Bio-Techne deal follows a multi-year consolidation wave in life sciences tools. Danaher spun off its life sciences and diagnostics business into a new company. Thermo Fisher acquired PPD for $17.4B. Agilent, Waters, and Bruker have all made acquisitions. The logic is the same in every case: the companies that supply reagents, instruments, and services to drug developers occupy a uniquely durable position. Drug programs come and go. The tools to discover them are always needed.

Bio-Techne is particularly well positioned because it supplies the "building blocks" of drug discovery: recombinant proteins, antibodies, cytokines, and growth factors. These are the reagents that populate target validation assays, ADC conjugation experiments, cell therapy manufacturing protocols, and molecular glue screening platforms. Every trend we have covered this year (the ADC wave, molecular glue development, in vivo CAR-T, AI drug discovery) increases demand for high quality research reagents.

For drug developers: this deal means Bio-Techne's product catalog, pricing, and support will eventually be managed under Merck KGaA's MilliporeSigma umbrella. Whether that changes the customer experience remains to be seen.

💊 Revolution: From One Drug to a Franchise

When we first covered Revolution Medicines' daraxonrasib Phase 3 data on April 13, the story was a single drug in a single indication. Three months later:

Revolution now has three distinct data packages in pancreatic cancer: second line monotherapy (daraxonrasib, Phase 3), first line combination (daraxonrasib + chemo, AACR), and combination with a second mechanism (RM-055 + chemo, BIO). This is a multi-drug franchise being built in a disease that had no targeted therapies 12 months ago.

📊 H1 2026: The Final Numbers

As we close the first half of the year, here is where the industry stands:

The second half starts Monday. Medicare GLP-1 Bridge launches July 1. Section 232 tariffs hit July 31. Revolution's approval could come by September. Retatrutide TRIUMPH-2 and TRIUMPH-3 readouts are expected. And Lilly's Investment Community Meeting on December 7 will need to make sense of 14 deals spanning nine therapeutic areas.

👉 Visit The Pro Hub

Is your company listed in the BioMed Nexus directory? 2,104 companies across 14 categories. Claim or upgrade your listing →

Sponsorship slots for 2026 are limited. See packages and pricing →

NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →